Boc-L-Tyr(tBu)-OH

Boc-L-Tyr(tBu)-OH is a Boc-protected L-tyrosine building block bearing a tert-butyl-protected phenolic side chain, providing orthogonal protection for peptide assembly workflows. The protected amino group supports controlled coupling chemistry, while the tBu ether on the phenol helps maintain side-chain integrity during acid/base manipulations typical of peptide synthesis. This reagent is commonly selected when tyrosine residues must be introduced with minimized side reactions and later deprotection to reveal the native phenolic functionality.

1. Solid-Phase Peptide Synthesis

Boc-L-Tyr(tBu)-OH is used by peptide synthesis groups to incorporate a protected tyrosine residue into peptide sequences where the phenolic side chain must remain protected throughout chain elongation. The Boc-protected amino functionality supports stepwise assembly strategies used in custom peptide manufacturing and academic peptide chemistry, while the tert-butyl phenol protection helps prevent undesired phenol reactivity and side-chain modification during coupling and washing cycles. After synthesis, the protected tyrosine side chain can be unmasked under deprotection conditions compatible with the overall peptide protecting-group scheme, enabling downstream studies that require the native tyrosine hydroxyl.

2. Modified Peptide Development

Boc-L-Tyr(tBu)-OH is frequently employed in the preparation of tyrosine-containing peptide analogs for chemical biology and protein interaction studies, particularly when the phenolic group must be preserved until final processing. Researchers developing peptide probes, receptor-binding peptides, or enzyme substrate mimics often require clean, controlled access to tyrosine for later functionalization or for maintaining native-like hydrogen-bonding patterns in binding assays. The dual protection pattern (Boc on the amino terminus and tBu on the phenol) supports reproducible synthesis of tyrosine-bearing segments that can be carried through multi-step assembly before phenol deprotection and subsequent derivatization.

3. Pharmaceutical Intermediate Synthesis

Boc-L-Tyr(tBu)-OH is also used in medicinal chemistry and pharmaceutical intermediate development to generate tyrosine-derived protected fragments that feed into larger synthetic sequences. Process chemists and custom synthesis teams select this reagent when a protected tyrosine motif is needed as an intermediate for constructing peptidomimetic scaffolds, peptide-like building blocks, or coupling-ready derivatives where phenolic protection is required to avoid side reactions. The availability of a protected phenol and a protected amino functionality helps streamline downstream transformations by maintaining chemoselectivity until the target intermediate is assembled and deprotected at the appropriate stage.

4. Tyrosine Side-Chain Functionalization

Boc-L-Tyr(tBu)-OH supports workflows where tyrosine hydroxyl functionality is required after peptide or fragment synthesis, enabling controlled post-assembly modification. Chemical biology laboratories often use protected tyrosine building blocks to prepare peptides for subsequent derivatization steps such as hydroxyl-directed conjugation or incorporation into phosphorylation-mimicking or phenol-reactive labeling strategies, while avoiding premature phenol chemistry during earlier steps. By keeping the phenolic group protected during assembly, the reagent helps maintain product integrity and improves reproducibility when the final step requires access to the tyrosine hydroxyl for downstream functionalization.

1. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

2. TMEM16F and dynamins control expansive plasma membrane reservoirs

3. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

4. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

5. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction